Yanshengchao (Beijing) Biotechnology
First-in-class drugs for inflammatory and autoimmune diseases
About Yanshengchao (Beijing) Biotechnology
Yanshengchao (Beijing) Biotechnology Co., Ltd. is a biopharmaceutical company founded in 2022, based on the original research of Professor Qi Hai's team at Tsinghua University's School of Medicine. The company focuses on developing first-in-class (FIC) drugs targeting novel pathways for inflammatory and autoimmune diseases. Yanshengchao was co-founded by Dr. Wang Yifeng, who serves as the CEO.
The company's primary mission is to address the significant unmet clinical needs in treating autoimmune and inflammatory conditions, aiming to overcome challenges such as insufficient efficacy, high relapse rates, and notable side effects of existing therapies. Its business model revolves around the research and development of large-molecule antibody drugs and small-molecule drugs. Yanshengchao's core pipelines include YSC001, a candidate for treating various autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis by targeting a GPCR to delete pathogenic T and B cell subsets. Another key pipeline, YSC002, is a protease-targeting therapy for chronic inflammatory diseases such as chronic sinusitis with nasal polyps, asthma, and atopic dermatitis.
Yanshengchao has secured significant funding to advance its drug development programs. In August 2025, the company completed a Series Pre-A financing round of several hundred million RMB, led by Guosheng Capital. This was followed by a Series A round of a similar amount in December 2025, led by Cathay Capital. These funds are designated for the clinical development of YSC001, preclinical development of YSC002, and early validation of other pipelines, as well as for expanding its international strategy and collaborations with multinational pharmaceutical companies. The company has also entered into a strategic cooperation with Sanofi and Cathay Capital to promote the Chinese pharmaceutical innovation ecosystem.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 2
- Open positions
- None listed
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Drug Development, Autoimmune, Inflammatory Diseases, Immune System, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2025 | $28M | $110M | Qiming Venture Partners · Cathay Capital | ↗ |
Growth signals
Yanshengchao (Beijing) Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Yanshengchao (Beijing) Biotechnology in the Dongcheng District ecosystem
The Yanshengchao (Beijing) Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Cathay Capital
Qiming Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Yanshengchao (Beijing) Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Yanshengchao (Beijing) Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









